A Phase 2 interventional study of bevacizumab [Avastin] and capecitabine [Xeloda] in Liver Cancer, sponsored by Hoffmann-La Roche. Completed at 7 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-06-06.
Sponsored by Hoffmann-La Roche · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 30 studies testing bevacizumab in Liver Neoplasms — 4 open to participants now, 9 under way, 1 of them phase 3. Bevacizumab · Liver Neoplasms.
Among the 30 studies testing bevacizumab in Liver Neoplasms, this one is the 14th largest by enrollment, is one of 2 that started in 2005, is one of 18 in phase 2, and was the 15th registered.
1,346 studies on the registry are indexed under Liver Neoplasms; 335 are open to participants now.
Browse Liver Neoplasms studies →4 of the 30 studies testing bevacizumab in Liver Neoplasms are open now, in 3 countries. Recruiting first, the newest first:
Fujian Cancer Hospital · Sites in China
Ages 18–75
Second Affiliated Hospital of Guangzhou Medical University · Sites in China
Ages 18–75
The Methodist Hospital Research Institute · Sites in United States, Canada
Ages 18+
Shanghai Changzheng Hospital
Ages 18–75
By country, each count listing its studies:
Bevacizumab: first FDA approval 2004 (AVASTIN), first EMA approval 2005. What it is approved for, and how studies give it, is on its page →
Of the 243 Liver Neoplasms studies recruiting now, 137 (56%) set no upper age limit and 69 (28%) stop at 75 or younger; 14 take children under 18; 34 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
30 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 8 · Phase 2 20 · Phase 3 2 · Phase 4 2
First in 2003; this study’s year is marked. 2 started in 2005.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 45 is close to the median of 47 across 928 interventional studies indexed under Liver Neoplasms.
Median enrollment 40 across the 30 interventional studies. Of the 18 that completed or were terminated, 10 (56%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 30 have an industry lead sponsor. The 10 most frequent:
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 330 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
Hoffmann-La Roche has 5 studies filed under Liver Neoplasms — fewer than ten, so there is no comparison to draw.
4 of the studies testing bevacizumab in Liver Neoplasms that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03937830National Cancer Institute (NCI)Combined Treatment of Durvalumab, Bevacizumab, Tremelimumab and Transarterial Chemoembolization (TACE) in Subjects With Hepatocellular Carcinoma or Biliary Tract Carcinoma | 2026-12-31 |
| NCT05185505The Methodist Hospital Research InstituteAtezolizumab and Bevacizumab Pre-Liver Transplantation for Patients With Hepatocellular Carcinoma Beyond Milan Criteria | 2027-04-30 |
| NCT04524871Hoffmann-La RocheA Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (Morpheus-Liver) | 2027-07-30 |
| NCT06788171Fujian Cancer HospitalPULSAR Combined With PD-1 Ab and Chemotherapy Plus Bev. for CRLM | 2027-09-01 |
Add all 4 to your calendar (.ics) → With an account.
Among the 30 studies testing bevacizumab in Liver Neoplasms, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study will evaluate the efficacy and safety of oral Xeloda (capecitabine) plus intravenous Avastin (bevacizumab) in patients with advanced or metastatic liver cancer. The anticipated time on study treatment is 3-12 months.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: bevacizumab [Avastin] · Drug: capecitabine [Xeloda]
7.5mg/kg iv on day 1 of each 3 week cycle.
1600mg/m2/day po in 2 divided doses, on days 1 to 14 of each 3 week cycle.
Percentage of Participants With Objective Response (OR)
Percentage of participants with OR based on assessment of confirmed complete response (CR) or confirmed partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST). Confirmed responses were those that persisted on repeat imaging study at least 4 weeks after initial documentation of response. The best overall response achieved within the time from first drug administration to progressive disease or end of study was reported. CR was defined as complete disappearance of all target lesions and non-target disease, with the normalization of tumor marker levels. No new lesions. PR was defined as greater than or equal to (≥) 30 percent (%) decrease under baseline of the sum of diameters of all target lesions. The short axis was used in the sum for target lesions. Persistence of one or more non-target lesion(s) or/and maintenance of tumor marker levels above the normal limits. No new lesions.
Time frame: Screening; Weeks 6, 12, 18, 24, and 30; Every 3 months through follow-up
Percentage of Participants With Disease Control
The percentage of participants with disease control was based on assessment of confirmed CR, PR, or stable disease (SD) according to RECIST criteria. Confirmed responses were those that persisted on repeat imaging study at least 4 weeks after initial documentation of response. The best overall response achieved within the time from first drug administration to progressive disease or end of study was reported. CR was defined as complete disappearance of all target lesions and non-target disease, with the normalization of tumor marker levels. No new lesions. PR was defined as ≥ 30 % decrease under baseline of the sum of diameters of all target lesions. The short axis was used in the sum for target lesions. Persistence of one or more non-target lesion(s) or/and maintenance of tumor marker levels above the normal limits. No new lesions. SD was defined as not qualifying for PR or progressive disease.
Time frame: Screening; Weeks 6, 12, 18, 24, and 30; Every 3 months through follow-up
Time to Disease Progression - Percentage of Participants With an Event
Time to progression was measured from time of treatment commencement to time of disease progression, or the date of death. Participants who were not progressed at the time of study completion (including participants who died before progressive disease) or who were lost to follow-up were censored at the date of last tumor assessment.
Time frame: Screening; Weeks 6, 12, 18, 24, and 30; Every 3 months through follow-up
Time to Disease Progression
Time to progression was measured from time of treatment commencement to time of disease progression, or the date of death. Participants who were not progressed at the time of study completion (including participants who died before progressive disease) or who were lost to follow-up were censored at the date of their tumor assessment.
Time frame: Screening; Weeks 6, 12, 18, 24, and 30; Every 3 months through follow-up
Time to Disease Progression - Percentage of Participants Progression-free at 12 Months
Time to progression was measured from time of treatment commencement to time of disease progression, or the date of death. Participants who were not progressed at the time of study completion (including participants who died before progressive disease) or who were lost to follow-up were censored at the date of last tumor assessment.
Time frame: Day 1, Weeks 1-18, Weeks 24 and 30, then every 3 months until death.
Overall Survival - Percentage of Participants With an Event
Overall Survival was defined as the time in months from randomization to date of death due to any cause. Participants without an event were censored the last time they were known to be alive.
Time frame: Day 1, Weeks 1-18, Weeks 24 and 30, then every 3 months until death.
Overall Survival
Overall Survival was defined as the time in months from randomization to date of death due to any cause. Participants without an event were censored the last time they were known to be alive. Median Overall Survival was estimated using the Kaplan-Meier method.
Time frame: Day 1, Weeks 1-18, Weeks 24 and 30, then every 3 months until death.
Overall Survival - Percentage of Participants Event Free at 12 Months
Overall Survival was defined as the time in months from randomization to date of death due to any cause. Participants without an event were censored the last time they were known to be alive.
Time frame: Day 1, Weeks 1-18, Weeks 24 and 30, then every 3 months until death.
| Milestone | Bevacizumab/Capecitabine |
|---|---|
| Started | 45 |
| Completed | 15 |
| Not completed | 30 |
| Withdrew: Adverse event | 3 |
| Withdrew: Death | 1 |
| Withdrew: Insufficient therapeutic response | 25 |
| Withdrew: Refused treatment | 1 |
Percentage of participants with OR based on assessment of confirmed complete response (CR) or confirmed partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST). Confirmed responses were those that persisted on repeat imaging study at least 4 weeks after initial documentation of response. The best overall response achieved within the time from first drug administration to progressive disease or end of study was reported. CR was defined as complete disappearance of all target lesions and non-target disease, with the normalization of tumor marker levels. No new lesions. PR was defined as greater than or equal to (≥) 30 percent (%) decrease under baseline of the sum of diameters of all target lesions. The short axis was used in the sum for target lesions. Persistence of one or more non-target lesion(s) or/and maintenance of tumor marker levels above the normal limits. No new lesions.
| percentage of participants | Bevacizumab/Capecitabine |
|---|---|
| Percentage of Participants With Objective Response (OR) | 9.1 (2.5 to 21.7) |
The percentage of participants with disease control was based on assessment of confirmed CR, PR, or stable disease (SD) according to RECIST criteria. Confirmed responses were those that persisted on repeat imaging study at least 4 weeks after initial documentation of response. The best overall response achieved within the time from first drug administration to progressive disease or end of study was reported. CR was defined as complete disappearance of all target lesions and non-target disease, with the normalization of tumor marker levels. No new lesions. PR was defined as ≥ 30 % decrease under baseline of the sum of diameters of all target lesions. The short axis was used in the sum for target lesions. Persistence of one or more non-target lesion(s) or/and maintenance of tumor marker levels above the normal limits. No new lesions. SD was defined as not qualifying for PR or progressive disease.
| percentage of participants | Bevacizumab/Capecitabine |
|---|---|
| Percentage of Participants With Disease Control | 52.3 (36.7 to 67.5) |
Time to progression was measured from time of treatment commencement to time of disease progression, or the date of death. Participants who were not progressed at the time of study completion (including participants who died before progressive disease) or who were lost to follow-up were censored at the date of last tumor assessment.
| percentage of participants | Bevacizumab/Capecitabine |
|---|---|
| Time to Disease Progression - Percentage of Participants With an Event | 77.8 |
Time to progression was measured from time of treatment commencement to time of disease progression, or the date of death. Participants who were not progressed at the time of study completion (including participants who died before progressive disease) or who were lost to follow-up were censored at the date of their tumor assessment.
| months | Bevacizumab/Capecitabine |
|---|---|
| Time to Disease Progression | 2.8 (1.5 to 4.1) |
Time to progression was measured from time of treatment commencement to time of disease progression, or the date of death. Participants who were not progressed at the time of study completion (including participants who died before progressive disease) or who were lost to follow-up were censored at the date of last tumor assessment.
| percentage of participants | Bevacizumab/Capecitabine |
|---|---|
| Time to Disease Progression - Percentage of Participants Progression-free at 12 Months | 24.0 (11.0 to 37.0) |
Overall Survival was defined as the time in months from randomization to date of death due to any cause. Participants without an event were censored the last time they were known to be alive.
| percentage of participants | Bevacizumab/Capecitabine |
|---|---|
| Overall Survival - Percentage of Participants With an Event | 77.8 |
Overall Survival was defined as the time in months from randomization to date of death due to any cause. Participants without an event were censored the last time they were known to be alive. Median Overall Survival was estimated using the Kaplan-Meier method.
| months | Bevacizumab/Capecitabine |
|---|---|
| Overall Survival | 5.9 (4.1 to 9.7) |
Overall Survival was defined as the time in months from randomization to date of death due to any cause. Participants without an event were censored the last time they were known to be alive.
| percentage of participants | Bevacizumab/Capecitabine |
|---|---|
| Overall Survival - Percentage of Participants Event Free at 12 Months | 27 (14.0 to 40.0) |
Collected over Adverse events were recorded from first intake of study medication until 28 days after the last intake of study medication with follow-up up until the event resolved or was adequately explained.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Bevacizumab/Capecitabine | — | 15/45 (33.3%) | 44/45 (97.8%) |
| Event | Bevacizumab/Capecitabine |
|---|---|
| Abdominal painGastrointestinal disorders | 2/45 |
| PyrexiaGeneral disorders | 2/45 |
| Abdominal pain upperGastrointestinal disorders | 1/45 |
| AscitesGastrointestinal disorders | 1/45 |
| DiarrhoeaGastrointestinal disorders | 1/45 |
| Diverticulum intestinalGastrointestinal disorders | 1/45 |
| Gastric ulcer haemorrhageGastrointestinal disorders | 1/45 |
| Gastric varices haemorrhageGastrointestinal disorders | 1/45 |
| Gastrointestinal haemorrhageGastrointestinal disorders | 1/45 |
| Oesophageal varices haemorrhageGastrointestinal disorders | 1/45 |
| Event | Bevacizumab/Capecitabine |
|---|---|
| Palmar-plantar erythrodysaesthesia syndromeSkin and subcutaneous tissue disorders | 15/45 |
| DiarrhoeaGastrointestinal disorders | 12/45 |
| Abdominal painGastrointestinal disorders | 11/45 |
| AnorexiaMetabolism and nutrition disorders | 10/45 |
| Oedema peripheralGeneral disorders | 9/45 |
| PyrexiaGeneral disorders | 9/45 |
| CoughRespiratory, thoracic and mediastinal disorders | 8/45 |
| Abdominal distentionGastrointestinal disorders | 7/45 |
| NauseaGastrointestinal disorders | 7/45 |
| InsomniaPsychiatric disorders | 7/45 |
All enrolled participants who received at least 1 dose of study drug.
| Age, Continuous(years) | Bevacizumab/Capecitabine |
|---|---|
| Mean | 52 ± 14.91 |
| Sex: Female, Male(Participants) | Bevacizumab/Capecitabine |
|---|---|
| Female | 5 |
| Male | 40 |
The record gives a start of May 2005, a primary completion of Mar 2008 and a completion of Mar 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Jun 2014, 6 years 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Bevacizumab · Capecitabine